14 May 2025 in Blood Cancer Journal
OGon behalf of the Spanish CETLAM Group
on behalf of the Spanish CETLAM Group
+23
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with
14 October 2026 in British Journal of Haematology
23 June 2026 in Blood Advances
2 November 2026 in European Journal of Haematology
Background: Isocitrate dehydrogenase ( IDH ) mutations are recurrent in acute myeloid leukemia (AML) and represent promising targets for measurable residual disease (MRD) monitoring. However, clinically validated strategies for IDH ‐based MRD assessment remain lacking. Methods: We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single‐center cohort of patients with IDH ‐mutated AML treated with curative intent. Healthy controls were included to characterize low‐level background signals and identify a clinical threshold. Results: ddPCR showed robust analytical performance, with a limit of detection of 0.01% variant allele frequency (VAF) and strong concordance with NGS. Low‐level IDH mutation signals were frequently detected in healthy individuals and in patients in remission. We identified 0.2% VAF as a candidate threshold for clinically relevant IDH MRD. Using this cutoff, post‐treatment detectable IDH MRD was associated with a higher 2‐year cumulative incidence of relapse (63.6% vs. 20%; p = 0.019) and inferior overall survival (70.6% vs. 92.9%; p = 0.04). Among patients negative by multiparameter flow cytometry, ddPCR identified residual IDH‐ mutated clones in 56% of cases, who showed higher relapse rates than double‐negative patients (50% vs. 0%; p = 0.031). Conclusions: A 0.2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH ‐based MRD assessment in AML.
29 October 2026 in Blood Advances
Prognostication in chronic myelomonocytic leukemia (CMML) remains a challenge because of the biological complexity and variable clinical course of the disease. This study aimed to evaluate the prognostic utility of the Molecular International Prognostic Scoring System (IPSS-M) in CMML and its applicability across the myelodysplastic (MD) and myeloproliferative (MP) subsets of the disease. We conducted a multicenter, retrospective study including 511 patients diagnosed with CMML. Clinical, cytogenetic, and molecular data were collected at diagnosis, including targeted next-generation sequencing. Patients were stratified using IPSS-M, the molecular CMML-specific prognostic scoring system (CPSS-Mol), and the recently developed international CPSS (iCPSS). IPSS-M effectively stratified patients into risk groups with significantly different overall survival (OS) and cumulative incidence of acute myeloid leukemia (AML) progression. Discrimination was maintained after merging overlapping intermediate-risk categories, yielding a 4-tier model with a C-index of 0.678 for OS and 0.628 for AML progression, respectively. This model retained its prognostic performance in both MD-CMML and MP-CMML subsets, with a higher discrimination for OS in the MD-CMML group. When compared with CPSS-Mol and iCPSS, adapted IPSS-M showed comparable prognostic performance to iCPSS and improved discrimination compared with CPSS-Mol. These findings support the applicability of an adapted IPSS-M to CMML, extending its use beyond myelodysplastic syndromes and highlighting its potential utility in guiding clinical decision-making and therapeutic strategies. Moreover, this study provides an external validation of the iCPSS in an independent and genetically well-characterized CMML cohort, reinforcing its clinical utility.